ARS Core Equity Portfolio ETF
ACEP · ETF
About ACEP
- Issuer
- ARS
- Expense ratio
- 0.46%
- Assets under management
- $100.63M
- Inception
- Nov 20, 2025
- Asset class
- Equity
- Website
- arsinvestetfs.com
ACEP key statistics
- Price-earnings ratio
- 0.00
- Average volume
- 1.49K
- Volume
- 697
- Open price
- $19.87
- High today
- $19.90
- Low today
- $19.82
- 52 Week high
- $20.99
- 52 Week low
- $15.03
ARS Core Equity Portfolio ETF (ACEP) at a glance
ARS Core Equity Portfolio ETF (ACEP) last traded at $19.90, with a price-to-earnings ratio of 0.00.
Today the fund has traded between $19.82 and $19.90. The current price is 0.4% above the day's low and 0.0% below its high.
Volume so far is 697 shares, below the average of 1.49K shares a day.
Over the past year ARS Core Equity Portfolio ETF has ranged from $15.03 to $20.99, and now sits 82% of the way up that range.
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- GTVHGolden Triangle Ventures$0.0002+100.00%
- TMSHTrans Global Assets$0.0003+20.00%
- RDARRaadr$0.0002+0.00%
- GPUSHyperscale Data$0.1689+34.05%
- SEIISharing Economy International$0.0002−33.33%
- ELMEElme Communities$1.77+0.57%
- SHFSSHF Holdings$0.1324−61.39%
- XXII22nd Century Group$0.1977−8.34%
- NBNDNetBrands$0.0006−40.00%
- NVDGraniteShares ETF Trust$4.19+0.96%
- HIRUHiru$0.0006+9.09%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.49−0.10%
- CTYCITY THERAPEUTICS$20.77+0.00%
- IAMIambic Therapeutics$14.26−2.79%
- AMROAmaero$5.84+7.75%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.30+0.29%
- TRXBTRex Bio$13.81−10.90%
- RTSNRetension Pharmaceuticals$15.25−1.61%
- PAXGUPine Tree Acquisition$10.01+0.05%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.13−0.77%
- ACCVAccelevation Holdings$12.38+1.06%
- RZAIROZE AI$10.92−1.89%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.